This protocol describes a survey undertaken to acquire a snapshot of the distribution of Clostridioides difficile strains in tertiary acute care hospitals in the European Union/European Economic Area (EU/EEA) in 2022–2023
This protocol sets out measures for the follow-up and management of individuals exposed to infected animals and human cases of avian influenza, and for the public health management of possible and confirmed human cases.
In 2020, the European Commission stressed the importance of continuously monitoring the safety and effectiveness of vaccines in the EU/EEA during the post-authorisation phase, with particular emphasis on COVID-19 vaccines in the context of the ongoing pandemic.
This document aims to provide guidance for public health and laboratory experts in identifying human infections with animal influenza viruses as early as possible to provide early warning and inform risk assessments and public health measures.
This document outlines operational considerations to support the continuity of national surveillance systems and public health laboratories for epidemiological and virological surveillance for influenza, SARS-CoV-2, and potentially other respiratory viruses in the 2022/2023 winter season and beyond.
This study provides insights for national public health authorities into the factors behind the spread of vaccine misinformation online and the options and capacities needed for responding to it.
The influenza vaccination communication guide provide advice, guidance and campaign materials to support national influenza vaccination campaigns with the purpose of increasing the influenza vaccination uptake in the EU Member States.
The aim of this guidance document is to provide EU/EEA Member States and EU bodies with relevant information to make an informed decision on routine vaccination of healthy children and pregnant women with seasonal influenza vaccine. The options presented in this document are based on a systematic review of the literature and the opinions of a group of independent experts.
This expert opinion is intended to support national decision-making by summarising the considerations and concerns of some EU/EEA countries when they discussed whether to introduce the 4CMenB vaccine into their national immunisation programmes.
This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States.